Lanraplenib
- Generic Name
- Lanraplenib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H25N9O
- CAS Number
- 1800046-95-0
- Unique Ingredient Identifier
- A6U64OU57E
- Background
Lanraplenib is under investigation in clinical trial NCT03285711 (Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Kronos Bio
- Target Recruit Count
- 24
- Registration Number
- NCT05028751
- Locations
- 🇪🇸
Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Barcelona, Spain
🇺🇸The Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
- Conditions
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT03285711
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
- Conditions
- Interventions
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 47
- Registration Number
- NCT03134222
- Locations
- 🇨🇦
K.Papp Clinical Research, Waterloo, Canada
🇨🇦Dermatology Ottawa Research Centre, Ottawa, Canada
🇺🇸St. Jude Hospital Yorba Linda DBA Dr. Joseph Heritage Healthcare, Fullerton, California, United States
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 152
- Registration Number
- NCT03100942
- Locations
- 🇺🇸
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Center for Rheumatology Immunology and Arthritis, Fort Lauderdale, Florida, United States
🇺🇸IRIS Research and Development, LLC, Plantation, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.